Possible clinical effects of macrolides on the treatment of primary pulmonary mucosa-associated lymphoid tissue lymphoma

详细信息    查看全文

• 作者：Kazuhiro Yatera ; Yuji Ishimatsu ; Noriho Sakamoto…
• 刊名：International Journal of Hematology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：103
• 期：2
• 页码：251-252
• 全文大小：529 KB
• 参考文献：1.Okamura I, Imai H, Mori K, et al. Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma. Int J Hematol. 2015;101(1):46–51.CrossRef PubMed
  2.Ferreri AJ, Sassone M, Kiesewetter B, et al. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncol. 2015;26:1760–5.CrossRef PubMed
  3.Ishimatsu Y, Mukae H, Matsumoto K, et al. Two cases with pulmonary mucosa-associated lymphoid tissue lymphoma successfully treated with clarithromycin. Chest. 2010;1383:730–3.CrossRef
  
• 作者单位：Kazuhiro Yatera (1)
  Yuji Ishimatsu (2)
  Noriho Sakamoto (3)
  Hiroshi Mukae (1)
  
  1. Department of Respiratory Medicine, University of Occupational and Environmental Health, 1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu City, Fukuoka, Japan
  2. Department of Cardiopulmonary Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  3. Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
  
• 刊物主题：Hematology; Oncology;
• 出版者：Springer Japan
• ISSN：1865-3774

文摘